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Abstract
Background & Aims: Tumour mutational burden (TMB) predicts improved response 
and survival to immunotherapy. In this pilot study, we optimized targeted next-gener-
ation sequencing (tNGS) to estimate TMB in hepatocellular carcinoma (HCC).
Methods: We sequenced 48 non-paired samples (21 fresh-frozen [FF] and 27 paraf-
fin-embedded [FFPE]), among which 11 FFPE samples were pretreated with uracil-
DNA glycosylase (UDG). Thirty samples satisfied post-sequencing quality control. 
High/low TMB was defined by median number of mutations/Mb (Mut/Mb), across 
different minimum allele frequency (MAF) thresholds (≥0.05, ≥0.1 and ≥0.2).
Results: Eligible patients (n = 29) were cirrhotic (84%) with TNM stage I-II HCC (75%). 
FFPE samples had higher TMB (median 958.39 vs 2.51 Mut/Mb, P < .0001), esti-
mated deamination counts (median 1335.50 vs 0, P < .0001) and C > T transitions at 
CpG sites (median 60.3% vs 9.1%, P = .002) compared to FF. UDG-treated samples 
had lower TMB (median 4019.92 vs 353 Mut/Mb, P = .041) and deamination counts 
(median 6393.5 vs 328.5, P = .041) vs untreated FFPE. At 0.2 MAF threshold with 
UDG treatment, median TMB was 5.48 (range 1.68-16.07) and did not correlate with 
salient pathologic features of HCC, including survival.
Conclusion: While tNGS on fresh HCC samples appears to be the optimal source of 
tumour DNA, the low median TMB values observed may limit the role of TMB as a 
predictor of response to immunotherapy in HCC.
K E Y W O R D S
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1  | INTRODUC TION
Hepatocellular carcinoma (HCC) is a malignancy with rising global 
incidence and a poor prognosis.1 Although treatment is curative 
in early stages, when surgical resection or transplantation can be 
employed, many patients are diagnosed at a late stage.2 Inoperable 
HCC is amenable to transarterial chemoembolization (TACE) or sys-
temic therapy with targeted kinase inhibitors, such as sorafenib and 
lenvatinib.3 In recent years, immune checkpoint inhibition (ICI) has 
become an emerging option for systemic therapy in advanced HCC.4
In HCC, the high levels of expression of immune checkpoint pro-
teins, such as programmed cell death protein (PD-1) and its ligands 
(PD-L1 and PD-L2), alongside the prominence of immune suppres-
sive cells in the HCC microenvironment,5 provide a biologic rationale 
for the use of immune checkpoint blockade-targeted immunother-
apy, and led to its investigation in clinical trials. Monoclonal agents 
against the PD-1 pathway, such as nivolumab and pembrolizumab, 
have been approved as second-line agents in advanced HCC.4,6,7 
However, the response rate to immunotherapy is approximately 
20%.8 While immunotherapy combinations are disrupting treatment 
paradigms in advanced HCC by inducing higher response rates and 
more convincing evidence of survival benefit, response to immuno-
therapy remains limited to a fraction of patients. When this is taken 
alongside the risk of treatment-related adverse events,7 some of 
which being potentially life-threatening, the acute need for predic-
tive biomarkers of response becomes apparent.
Tumour mutational burden (TMB) is an emerging genomic bio-
marker of response to immunotherapy.8 TMB is defined as the 
number of somatic non-synonymous mutations per mega-base of 
assayed genome and can be computed from tissue or circulating 
tumour DNA using whole-exome or targeted next-generation se-
quencing (tNGS). Non-synonymous mutations can result in structur-
ally distinct mutant protein products, which can act as neoantigens, 
increasing the probability of T-cell recognition of the tumour.9 As a 
result, a higher number of non-synonymous mutations may account 
for clinically meaningful increase in the probability of response to 
immunotherapy, lending TMB as a putative genomic trait that can be 
used to stratify patients on the basis of their likelihood of response 
to ICI.10-15
In the field of HCC, a conclusive evaluation of the correlation 
between TMB and outcomes from immunotherapy is not available 
to date, largely because of the low proportion of patients requir-
ing histological confirmation of the diagnosis prior to treatment.16 
Furthermore, most studies evaluating TMB as a predictive biomarker 
have utilized whole-exome sequencing techniques, which are ex-
pensive, characterized by long turnaround times and require bioin-
formatic expertise for interpretation.17 For TMB to be a valuable and 
clinically applicable response biomarker in HCC, it requires a method 
of derivation from routinely collected samples that is reproducible 
and feasible in day-to-day clinical practice. In this pilot study, we de-
scribe the optimization of TMB estimation using tNGS on archival 
and fresh HCC samples in a view to facilitate its development as a 
biomarker of response to ICI.
2  | MATERIAL S AND METHODS
2.1 | Patient cohort
Samples from 60 HCC patients were included in the study. Samples 
were derived from the Imperial College Healthcare NHS Trust tissue 
bank and included biopsies or resections performed between 2000 
and 2019. All subjects gave their informed consent for inclusion in 
research prior to sample retrieval.
A subset of our patients (n = 4) was treated with pembrolizumab 
200 mg intravenously every 3 weeks until subject withdrawal due 
to disease progression or toxicity. In these patients, tumours were 
biopsied at 28 days prior to dosing.
2.2 | Sample preparation
Samples were provided either as formalin-fixed paraffin-embedded 
(FFPE) blocks or fresh-frozen (FF) tissues.
FFPE tissue blocks were sectioned into 5 µm slices using a mi-
crotome and macro-dissected to ensure >20% tumour content. 
EchoSAFE FFPE Deparaffinization Solution kit (BioEcho Life Science 
GmBH, Germany) was used to deparaffinize sectioned FFPE tissue 
slices, using four slices of 5 µm FFPE tissue sections for each sample. 
The type, amount and working conditions of lysis buffer and protein-
ase followed instruction of AllPrep® DNA/RNA FFPE kit (QIAGEN, 
Venlo, NL, USA). Fresh-frozen tissues were placed on dry ice and 
sectioned into cubes of <30 mg using a sterilized scalpel.
2.3 | Nucleic acid extraction and preparation
In total, 60 tumour tissue samples (39 FFPE and 21 FF) were uti-
lized. From FFPE tissues, DNA was extracted using AllPrep® DNA/
RNA FFPE kit (QIAGEN). Lysis buffer loading and proteinase were 
performed during the deparaffinization step, as per the EchoSAFE 
FFPE Deparaffinization protocol. Sectioned FF cubes were placed 
into 2.0 mL tubes containing 1.4 mm Precellys ceramic beads (Bertin 
Instruments, Montigny-le-Bretonneux, France) and homogenized 
by Precellys 24 homogenizer (Bertin Instruments). RNA, DNA and 
proteins were extracted using AllPrep® DNA/RNA/Protein Mini 
kit (QIAGEN). To minimize the effect of cytosine deamination-in-
duced mutation artefacts on TMB, FFPE samples were treated with 
Lay Summary
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heat-liable uracil-DNA glycosylase (UDG) (Thermo Fisher Scientific, 
Loughborough, UK), according to the Oncomine™ TML assay pro-
tocol. Absorbance-based NanoDropTM 1000 Spectrophotometer 
(Thermal Fisher Scientific) was used for both DNA and RNA quan-
tification. Fluorescence-based Qubit® double-stranded DNA High 
Sensitivity Assay Kit (Life Technologies, Carlsbad, Germany) was 
performed for further DNA quantification.A
Formalin-fixed paraffin-embedded tissue DNA samples with 
A260/280 above 1.7 and A260/230 above 1.7 measured by NanoDrop
™ 
spectrophotometer were prioritized, and those with adequate intact 
double-strand DNA quantity (≥3.08 ng/µL) measured by Qubit® 2.0 
fluorometer (Life Technologies) were selected for UDG treatment 
and subsequent sequencing to obtain TMB and variant calls.
Fresh-frozen tissue DNA samples with A260/280 above 1.7 and 
A260/230 above 1.7 measured by NanoDrop
™ spectrophotometer 
were prioritized, and those with adequate intact double-strand DNA 
quantity (≥0.67 ng/µL) were selected for the Oncomine™ TML assay 
library preparation.
2.4 | Gene-targeted panel sequencing
The Ion Torrent™ Oncomine™ Tumour Mutation Load (TML) Assay 
was employed for tissue DNA sequencing. Ion AmpliSeq™ library 
preparation kit (Life Technologies) was employed for use with Chef 
DL8 (Life Technologies) on the automated Ion Chef™ system (Life 
Technologies).
Diluted UDG-treated FFPE DNA samples or FF DNA samples 
were loaded into the Ion Torrent™ 96-well PCR plate containing sam-
ple-specific barcodes and proceeded for library preparation.
Gene-specific primer pools of Ion Torrent™ Oncomine™ TML 
Assay (Life Technologies) were employed, targeting 408 genes for 
tumour profiling (Table S1).
The Torrent Suite online platform (Thermo Fisher Scientific) was 
used to input and record sample details for library preparation and 
templating. RNase-free water-diluted libraries at 50 pmol/L in 25 µL 
were loaded into Ion Chef™ system for templating onto the Ion 540™ 
Chips (Life Technologies).18 Freshly templated chips were placed 
into Ion S5™ sequencer (Life Technologies) for tNGS within 1 hour of 
completion of templating.
Samples with uniformity and mean depth coverage over 80% and 
300, respectively, in the quality control report of the sequence run 
were selected for further data analyses. Among 48 sequenced tissue 
samples, a final pool of 30 tissue samples (six untreated FFPE; six 
UDG-treated FFPE; and 18 FF) from 29 patients passed sequencing 
quality check and were subjected to downstream analyses.
2.5 | Data analysis
The Ion Reporter (Thermo Fisher Scientific) online platform and 
‘Oncomine TML -w2.0-DNA-Single Sample’ analysis workflow 
were employed to calculate the TMB of samples. Minimum allele 
frequency (MAF) thresholds were adjusted to 10% and 20% as com-
pared to default 5% for optimization.
Data were stratified according to sample preservation meth-
ods (FFPE vs FF), DNA pretreatment groups (untreated FFPE vs 
UDG-treated FFPE), MAF filtering thresholds in analysis work-
flow (MAF0.05 vs MAF0.1 vs MAF0.2), immunotherapy responses 
(responder vs non-responder), clinical parameter statuses (pres-
ence vs absence) and TMB groups (high vs low cut-off by median). 
Clinicopathologic data including patient demographics, tumour size 
and stage, liver function, plasma alpha foetoprotein (AFP) level, sta-
tus of hepatitis viral infection, pattern of alcohol intake and survival 
were analysed anonymously for their relationship with TMB.
All statistical tests were performed with IBM SPSS Statistics 
(IBM Corporation, Armonk, NY, USA) software package. Mann-
Whitney and Kruskal-Wallis tests were performed in two-tailed 
non-parametric manner to illustrate statistical differences of TMB 
in different parameter groups. Kaplan-Meier survival plots were 
constructed and log-rank (Mantel-Cox) tests were performed to ex-
amine the effect of TMB level on patient's overall survival (OS). We 
performed non-parametric Spearman Rho's test to investigate the 
association between TMB level and tumour size.
3  | RESULTS
3.1 | Patient cohort
In total, 48 archival tissues samples from 47 patients who under-
went liver resection (n = 16), TACE (n = 9) or transplantation (n = 6) 
for HCC were included (FFPE n = 27; FF n = 21) (Figure 1). Samples 
were sequenced using the Oncomine™ TML Assay. The final analy-
sis included 30 samples from 29 patients following exclusion of 18 
samples that did not meet quality criteria for analysis (ie uniform-
ity >80% and mean depth coverage >300). Clinical features of 29 
evaluable patients are described in Table 1. The majority of patients 
included were male (83.9%) and cirrhotic (83.9%).
3.2 | Optimization of TMB measurement
A total of 30 tissue DNA samples from 29 patients that were se-
quenced utilizing the Oncomine™ TML assay panel satisfied the 
quality criteria for uniformity and coverage of sequencing and were 
deemed suitable for downstream analysis. We optimized the TMB 
measurement by comparing total number of non-synonymous muta-
tions, deamination counts, somatic variant counts and non-synony-
mous variant counts and somatic mutation signatures according to 
different sample preservation methods (FFPE vs FF sample), DNA 
pretreatment methods and MAF thresholds in post-sequencing 
analysis.
We noted that FFPE DNA displayed significantly higher TMB (me-
dian 958.39 vs 2.51 Mut/Mb, IQR 9901.79 vs 3.77, P < .0001), esti-
mated deamination counts (median 1335.50 vs 0, IQR 16 075 vs 1, 
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P < .0001), somatic variant counts (median 1622.5 vs 6, IQR 17 240 
vs 8, P < .0001) and non-synonymous variant counts (median 786.5 
vs 3, IQR 4185 vs 4.5, P < .0001), when compared to FF tumour sam-
ples (Figure 2). Over three quarters of FFPE samples had TMB and 
deamination counts exceeding the maximum acceptable thresholds 
(ie TMB ≤ 100 Mut/Mb; deamination count ≤30), while all FF samples 
yielded interpretable TMB values and acceptable deamination counts.
Uracil-DNA glycosylase treatment was performed prior to se-
quencing of FFPE samples to optimize TMB measurement. UDG-
treated FFPE samples carried significantly lower TMB (median 
4019.92 vs 353 Mut/Mb, IQR 7730.91 vs 400.83, P = .041), esti-
mated deamination counts (median 6393.5 vs 328.5, IQR 12 085.75 
vs 310, P = .041), somatic variant counts (median 6901.5 vs 548, IQR 
17 179 vs 578, P = .041) and non-synonymous variant counts (me-
dian 3227 vs 294, IQR 7980 vs 323, P = .041; Figure 3).
Formalin-fixed paraffin-embedded samples displayed signifi-
cantly higher proportion of C > T transitions at CpG sites, including 
at AG[CG] and at CT[CG], and especially C > T transition at NCC, 
CC[ACT] and TC[ACT] (median 60.3% vs 9.1%, P = .002) (Table S1). 
UDG-treated FFPE had significantly lower C > T transitions at non-
CpG sites, including NCC, CC[ACT] and CT[ACT] (P = .041), and 
C > T at other sites (P = .041), for an overall reduction of over 96%. 
Although this did not reach statistical significance, at CpG sites there 
was a reduction of over 50%, including [AG]CG (P = .180) and [CT]
CG (P = .240) (Table S2).
At the default MAF for detection of 5%, UDG-treated FFPE and 
untreated FFPE had cumulatively over 90% of somatic variant allele 
frequency clustered and skewed at class intervals below 20% allele 
frequency. FF samples displayed more normally distributed allele 
frequencies, peaked between 40%-50% and 50%-60% class interval 
allele frequencies, and less than 20% of somatic variants detected 
were clustered at allele frequency class intervals below 20%, that is 
5%-10% and 10%-20% (Figure 4).
In UDG-treated (UDG+) and untreated (UDG−) FFPE samples, 
adjustment from MAF0.05 to MAF0.2 resulted in significantly re-
duced TMB (P = .002 for UDG+, P = .009 for UDG−), estimated 
deamination counts (P = .001 for UDG+ and UDG−), somatic vari-
ant counts (P = .002 for UDG+, P = .009 for UDG−) and non-syn-
onymous variant counts (P = .001 for UDG+, P = .009 for UDG−) 
(Figures S1 and S2). There was a significant reduction in all somatic 
mutation signatures (ie C > T at [AG]CG, [CT]CG, NCC/CC[ACT]/
TC[ACT] sites or others) (Table S3). Overall, raising MAF threshold to 
20% resulted in both interpretable TMB and acceptable deamination 
counts.
In FF samples, comparison of MAF thresholds applied revealed 
no statistically significant differences in TMB (P = .833), estimated 
deamination counts (P = .254), somatic variant counts (P = .840) and 
non-synonymous variant counts (P = .850) among all three MAF 
thresholds (Figure S3). All TMB and deamination counts derived 
from all three MAF thresholds were interpretable and acceptable. 
F I G U R E  1   Schematic diagram to 
show sample disposition and processing. 
After extraction and quantification, 
DNA derived from FFPE tumour tissue 
was treated with UDG. Following this, 
samples that passed quality check and 
underwent targeted panel sequencing 
using Oncomine™TML assay. After further 
quality check filtering and selection 
and MAF threshold adjustment, TMB 
measurement and variant calling were 
performed. TMB was then correlated 
with patient data on clinical parameters 
and outcomes. FFPE, formalin-fixed 
paraffin-embedded; HCC, hepatocellular 
carcinoma; MAF, minimum allele 
frequency; TMB, tumour mutational 
burden; TML, Tumour Mutation Load; 
UDG, uracil-DNA glycosylase
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Moreover, there were no statistically significant differences in any 
somatic mutation signature counts (P > .8) by MAF threshold adjust-
ment (Table S4).
Comparison of untreated FFPE to FF samples at MAF0.2 thresh-
old revealed significantly higher TMB (median 34.79 vs 1.69 Mut/
Mb, IQR 93.99 vs 2.94, P = .017), somatic variant counts (median 90 
vs 5, IQR 201.5 vs 6, P = .003) and non-synonymous variant counts 
(media 37 vs 2, IQR 83.75 vs 4, P = .010) in untreated FFPE samples. 
By contrast, comparison of UDG-treated FFPE to FF samples did not 
show any statistical differences in TMB (median 5.48 vs 1.69 Mut/
Mb, IQR 8.11 vs 2.94, P = .291), somatic variant counts (median 15 
vs 5, IQR 17 vs 6, P = .069) and non-synonymous variant counts 
(median 6 vs 2, IQR 10 vs 4, P = .238). This demonstrated that MAF 
adjustment alone was not sufficient to optimize TMB measurement, 
while combination of UDG treatment and MAF threshold adjust-
ment to 20% led to a reduction in TMB values to best match the 
levels measured in FF samples (Figure 5).
Finally, we evaluated the impact of MAF threshold readjustment 
in variant calling in FFPE and FF samples. At MAF0.2, there were 
112 non-synonymously mutated genes found in untreated FFPE 
samples, 38 found in UDG-treated FFPE samples and 32 found in 
FF samples. Collectively, 34 non-synonymously mutated genes and 
gene combinations were found in two or more sample groups at 
MAF0.2 threshold, and only two genes (ie KMT2C and TAF1L) were 
found common among all sample groups (Table 2).
3.3 | Relationship between TMB and 
clinical outcomes
In our cohort, median OS was 12.3 months (95% CI 1-40). OS was 
stratified based on median TMB detected at MAF0.2 threshold in 
untreated FFPE, UDG-treated FFPE and FF samples independently 
(Figure 6). Comparison of OS in low vs high MAF0.2 TMB groups 
of untreated FFPE (P = .114), UDG-treated FFPE (P = .988) and FF 
(P = .738) samples was not statistically significan
Correlation of TMB to clinical-pathological outcomes of patients 
was tested independently for untreated FFPE, UDG-treated FFPE 
and FF samples due to differential distribution of TMB at MAF0.2 
threshold among sample groups. Tumour size was significantly cor-
related with TMB at MAF0.2 threshold in untreated FFPE samples 
(correlation coefficient = .88, P = .021), while no statistical correla-
tion to TMB at MAF0.2 threshold was observed in UDG-treated 
FFPE (correlation = .205, P = .741) and FF (correlation = .375, 
P = .153) (Figure S4). There was no significant correlation between 
TMB and viral infection status, presence of cirrhosis, alcohol con-
sumption and level of plasma AFP, across all sample groups (P > .05 
for all correlations).
Of the 34 genes found to be non-synonymously mutated across 
two sample groups, four genes were highlighted as commonly found 
in top 20 mutated genes in HCC reported in COSMIC database and 
in our study at MAF0.2 threshold. OS of patients was stratified ac-
cording to the mutation status of genes. Among these four genes, 
that is KMT2D (P = .771), KMT2C (P < .001), HNF1A (P = .652) and 
LRP1B (P = .586), mutation of KMT2C demonstrated significantly 
shorter OS duration in patients (30.1 vs 1 month).
Our cohort included four patients with sequenced FF DNA 
treated with pembrolizumab. Their OS from diagnosis ranged from 
0.9 to 13.1 month(s). Only three patients were evaluable for re-
sponse based on RECIST 1.1 criteria and were included in our ex-
ploratory analysis. Response was observed in two of three patients. 
Comparison of TMB at MAF0.2 between patients who achieved an 
objective response and those who did not revealed no statistical dif-
ferences (median 0.745 vs 0 Mut/Mb, P = 1.000). Three non-syn-
onymously mutated genes, CIC, PIK3R1 and TSC2, were detected at 
default MAF 5% threshold in immunotherapy recipients. All patients 
carried missense mutations in CIC gene and one responder carried 
missense mutation for all three genes.
4  | DISCUSSION
The treatment landscape of advanced HCC is changing at a rapid 
pace, with ICI having become a therapeutic option as a first- and sec-
ond-line therapy in patients with unresectable disease.19 The choice 
between immunotherapy combination between atezolizumab and 
bevacizumab in first-line, over PD-1 targeting agents 20,21 with or 
without CTLA-4 inhibitors in second-line,22 is dictated by clinical 
characteristics of the patients and reimbursement considerations. 
There are no reliable biomarkers to allow effective molecular triaging 
TA B L E  1   Clinical characteristics of patient samples passing 
sequencing quality check (ie uniformity > 80% and mean depth 
coverage > 300)




Age, median (range) 62 (34 to 89)
Cirrhosis 24 (83)
HBV infection 3 (10)
HCV infection 13 (45)
Alcoholic consumption 13 (45)




Treatment, n = 29
Resection 16 (55)
Transarterial chemoembolization 9 (31)
Transplantation 6 (21)
Pembrolizumab 4 (14)
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of patients towards the most appropriate therapy in HCC, where 
PD-L1 immunostaining has demonstrated limited reproducibility and 
inadequate linkage with clinical outcomes.23-25 Genomic determi-
nants of response to immunotherapy have been under intense scru-
tiny across malignancies. For instance, the presence of mutations in 
the beta-catenin pathway has been associated with an immune-ex-
cluded phenotype in HCC,26 suggesting a therapeutically appealing 
relationship between mutations in candidate loci and the immune 
suppressive characteristics of the tumour microenvironment.
Tumour mutational burden is an emerging biomarker of response 
to immunotherapy across oncological indication. Tumours harbour-
ing higher levels of non-synonymous mutations by whole-exome se-
quencing analysis have been shown to be intrinsically responsive to 
immunotherapy.27
In this pilot study, we aimed to verify whether tNGS can be rou-
tinely utilized as a measure of patients’ TMB in patients with HCC. 
Unlike WES, tNGS is widely available across institutions, being rou-
tinely employed for testing of actionable mutations in solid tumours. 
tNGS platforms with lower coverage and depth of sequencing have 
been successfully implemented as a way of testing for patients’ TMB 
status in tumours other than HCC.28 Moreover, tNGS is generally 
suitable for analysis of FFPE samples.29
Using a commercially available TMB platform, we optimized the 
methodology of TMB measurement in archival and fresh samples 
from patients with HCC and evaluated TMB as a prognostic bio-
marker for this condition.
During optimization, we reproduced the finding that FFPE 
samples contain more deaminated artefact mutations than FF 
samples.30,31 Specifically, we found significantly higher C > T deam-
ination at [AG]CG and [CT]CG, which were at CpG sites; as well as 
C > T deamination at NCC, CC[ACT] and TC[ACT], compared to FF 
samples. In absence of any treatment, the levels of TMB appeared to 
be significantly altered by fixation artefacts, making interpretation 
of patients’ TMB status particularly challenging. These findings bring 
to question the practicality of using FFPE samples to derive TMB as 
a biomarker. To address this, we investigated the ways of reducing 
the amount of deamination artefact in FFPE sample with UDG treat-
ment prior to sequencing. UDG is an enzyme that prevents mutagen-
esis by eliminating from DNA molecules the uracil that results from 
cytosine deamination. Although UDG treatment achieved a reduc-
tion of TMB and deamination by over 90%, TMB values remained 
above the recommended interpretable limit of 100 Mut/Mb, while 
deamination counts remained above 30/Mb.
In order to achieve interpretable TMB levels, we investigated 
the effect of adjusting the MAF threshold to filter low prevalent 
mutations that are likely to represent artefacts. Regardless of DNA 
pretreatment with UDG, the significantly lowered TMB and de-
amination base counts, and significant reduction in all mutation 
F I G U R E  2   Box-and-Whisker plots to show comparison of (A) TMB, (B) estimated deamination, (C) somatic variants and (D) non-
synonymous variants between sample preservation method groups (FFPE vs fresh-frozen tumour tissue) at default filter chain setting 
(MAF0.05) by non-parametric two-tailed Mann-WhitneyUtest. Total n = 25 (FFPE = 12; fresh-frozen = 13). Maximum interpretable 
TMB = 100 Mut/Mb; maximum acceptable estimated deamination count = 30. Level of statistical significance indicated by *<.05; **<.01; 
***<.001 and ****<.0001. FFPE, formalin-fixed paraffin-embedded; MAF, minimum allele frequency; TMB, tumour mutational burden
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signature patterns under MAF0.2 threshold over MAF0.05 revealed 
that adjustment of MAF threshold to 20% was effective in reducing 
the impact of fixation artefacts in affecting the overall TMB read-
ing. MAF threshold adjustment proved an effective methodology 
for all sample groups, with most FFPE and all FF samples attaining 
interpretable TMB level under MAF0.2 threshold. Additionally, ad-
justment to MAF0.2 greatly reduced the differences in the number 
of mutations detected between FFPE and FF samples (Figures 2 and 
4), highlighting its importance for variant detection alongside TMB 
measurement. Altering the MAF threshold increased the probability 
F I G U R E  3   Box-and-Whisker plots to show comparison of (A) TMB, (B) estimated deamination, (C) somatic variants and (D) non-
synonymous variants between DNA pretreatment groups (untreated FFPE vs UDG-treated FFPE) at default filter chain setting (MAF0.05) 
by non-parametric two-tailed Mann-WhitneyUtest. Total n = 12 (untreated FFPE = 6; UDG-treated FFPE = 6). Maximum interpretable 
TMB = 100 Mut/Mb; maximum acceptable estimated deamination count = 30. Level of statistical significance indicated by *<.05; **<.01; 
***<.001 and ****<.0001. FFPE, formalin-fixed paraffin-embedded; MAF, minimum allele frequency; TMB, tumour mutational burden; UDG, 
uracil-DNA glycosylase
F I G U R E  4   Percentage distribution 
of somatic variant allele frequency of 
UDG-treated FFPE, untreated FFPE and 
fresh-frozen tumour tissue samples. Total 
n = 25 (UDG-treated FFPE = 6; untreated 
FFPE = 6; fresh-frozen = 13), 408 genes 
included for allele frequency detection 
at default MAF0.05 filtering threshold. 
Error bar presented in one standard error 
from mean value. FFPE, formalin-fixed 
paraffin-embedded; MAF, minimum allele 
frequency; UDG, uracil-DNA glycosylase
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of filtering out low-frequency variables that are subclonal in na-
ture and reflect intratumour heterogeneity (ITH), something which 
has been reported previously in HCC at a frequency of 5%-10%.32 
Indeed, in our FF samples, approximately 10% of variants were de-
tected at 5%-10% allele frequency and may be accounted for by ITH. 
It follows, therefore, that MAF threshold adjustment to 0.2 in FFPE 
samples may render ITH indistinguishable from mutation artefact 
but permits more accurate TMB calculations.
Comparison of TMB under MAF0.2 derived from UDG-treated 
FFPE to that derived from untreated FFPE samples demonstrated 
that UDG treatment further reduced the TMB value and deami-
nation artefact contributions from FFPE-related sites (ie C > T at 
NCC, CC[ACT] and TC[ACT]). The combined effects of UDG treat-
ment and MAF adjustment were shown significant by comparison of 
TMB under MAF0.05 threshold from untreated FFPE to TMB under 
MAF0.2 threshold from UDG-treated FFPE. Therefore, combined 
UDG treatment with MAF0.2 threshold adjustment is expected to 
lend to best outcomes on both TMB interpretation as well as single 
variant detection.
Following optimization, the correlation of TMB with common 
clinicopathological outcomes and features was investigated. We 
concentrated on a subset of samples that were adequate based on 
stringent quality control criteria (Figure 1). Due to the fact that TMB 
values were found to distribute differently across preservation and 
presequencing treatment sample groups, samples were stratified ac-
cording to how they were prepared, due to the limited availability of 
matched untreated FFPE, UDG-treated FFPE and FF samples from 
the same individual.
Tumour size was the only feature found to correlate with TMB, 
and this was found in untreated FFPE samples. This is in keeping 
with a previous study in HCC, which did not demonstrate a cor-
relation between TMB or other genomic differences and clinical 
outcomes, including OS.16 However, it should be noted that the 
fairly limited sample size and stage heterogeneity of our cohort 
preclude us from drawing definitive conclusions as to the prog-
nostic role of TMB in HCC, a point that should be explored in 
future studies.
Among the non-synonymously mutated genes derived from tar-
geted sequencing, we looked at specific mutations known to be more 
prevalent in HCC and investigated their impact on outcome. The 
gene KMT2C was detected at both MAF0.05 and MAF0.2 thresholds 
among all sample groups and was found to be significantly associ-
ated with OS. Detection of KMT2C, one of the top 20 cancer-driving 
mutations for HCC in the COSMIC database, confirms that potential 
key driver mutations in HCC are detectable in a panel selected for 
tNGS in our study.
Our investigation of the use of TMB as a prognostic biomarker for 
immunotherapy in HCC was limited by the small number of patients, 
F I G U R E  5   Box-and-Whisker plots to show comparison of (A) TMB, (B) estimated deamination, (C) somatic variants and (D) non-
synonymous variants between sample groups (untreated FFPE vs UDG-treated FFPE vs fresh-frozen) at Oncomine™Tumour Mutation 
Load (TML) assay filter chain MAF0.2 threshold by non-parametric two-tailed Kruskal-Wallis test with multiple comparisons. Total n = 25 
(untreated FFPE = 6; UDG-treated FFPE = 6; fresh-frozen = 13). Maximum interpretable TMB = 100 Mut/Mb; maximum acceptable 
estimated deamination count = 30. Level of statistical significance indicated by *<.05; **<.01; ***<.001 and ****<.0001. FFPE, formalin-fixed 
paraffin-embedded; MAF, minimum allele frequency; TMB, tumour mutational burden; UDG, uracil-DNA glycosylase
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with only three patients being evaluable following pembrolizumab 
treatment. As such, this study was not powered to detect the dif-
ferences in TMB between immunotherapy responders and non-re-
sponders using the Oncomine™ TML assay, and can only provide a 
preliminary, descriptive evaluation. We found no difference in TMB 
distribution between responders and non-responders to immuno-
therapy, where no patients had TMB values >10 Mut/Mb. Further 
research is required to fully address this question.
We recognize significant limitations to our study. Firstly, we 
have to take into account inter-sample differences given the 
groups of untreated, UDG-treated FFPE and FF DNA samples were 
not extracted from the same tumours. In addition, DNA integrity is 
inversely proportional to the duration of tissue fixation.33 Because 
our study included archival material processed during routine care, 
we cannot confidently reconstruct the influence of fixation on 
DNA quality. A better study design would have entailed pairwise 
Rank
Non-synonymously mutated gene/
gene combination at MAF0.2




1 KMT2D* 22.55 41.59 13.3
2 TAF1L 20.09 45.59 13.3
3 ADGRA2 20.00 23.76 10.0
4 ADGRL3 28.57 59.07 10.0
5 BCYRN1|TAF1 22.76 33.73 10.0
6 CREBBP 24.76 51.43 10.0
7 EP300 23.23 47.99 10.0
8 GATA1 20.00 22.15 10.0
9 KDM5C 20.36 30.53 10.0
10 KMT2C* 22.70 33.25 10.0
11 NOTCH4 21.05 26.69 10.0
12 NTRK1 24.81 36.79 10.0
13 TBX22 21.55 56.74 10.0
14 ACVR2A 22.86 87.00 6.7
15 AFF3 21.74 39.96 6.7
16 AKAP9 29.33 44.62 6.7
17 ASXL1 20.61 42.68 6.7
18 BLM 20.88 51.10 6.7
19 CDKN2B 22.86 24.71 6.7
20 CSF1R 22.14 66.67 6.7
21 CSMD3 27.21 40.54 6.7
22 HNF1A* 22.92 39.11 6.7
23 ITGB3 47.57 48.59 6.7
24 LRP1B* 21.80 29.07 6.7
25 MAGEA1 20.41 99.81 6.7
26 MAML2 26.47 53.38 6.7
27 MN1 21.88 22.43 6.7
28 NBPF19 22.77 39.53 6.7
29 NBPF20 22.00 23.21 6.7
30 NF2 20.18 32.32 6.7
31 NUMA1 20.29 50.83 6.7
32 PAX3 20.60 67.97 6.7
33 RNF213 22.29 31.07 6.7
34 MAP2K2 25.74 32.22 6.7
Note: Abbreviations: FFPE, formalin-fixed paraffin-embedded; HCC, hepatocellular carcinoma; 
UDG, uracil-DNA glycosylase.
TA B L E  2   Ranked list of non-
synonymously mutated gene and gene 
combinations found in two or more 
sample groups (ie UDG-treated FFPE, 
untreated FFPE and fresh-frozen) based 
on mutation frequency. A total of 34 
non-synonymously mutated genes and 
gene combinations were ranked based 
on mutation frequency. Asterisks (*) 
indicate genes appeared on the list of 
Top 20 mutated genes in HCC patients in 
the COSMIC database. Allele frequency 
of mutated genes detected at default 
5% minimum allele frequency threshold. 
Mutation frequency was calculated by 
number of mutated samples per gene 
divided by number of total samples 
included. Total n = 30
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evaluation of fresh and FFPE samples from the same tumours, 
controlling for fixation time. Our study followed a more pragmatic 
design: to ensure sufficient statistical power to allow correlation 
with clinical outcomes, we opted to include the maximum number 
of consecutive patients to generate an adequate sample size for 
hypothesis testing. Another important limitation of this work is 
that there is lack of consensus in TMB cut-off threshold for HCC 
in the literature. Therefore, this study employed the median value 
of non-synonymous mutations as the cut-off threshold to stratify 
patients into ‘high’ and ‘low’ TMB groups. Lastly, our study did not 
address the impact of intratumoural heterogeneity on TMB esti-
mation, a point of greater consequence given that regional expres-
sion of passenger mutations leads to clonal expansion of adaptive 
immune cells in HCC.34
5  | CONCLUSIONS
This study describes the optimization approaches for the de-
termination of TMB in HCC at pre- and post-sequencing levels. 
Utilization of FF samples should be prioritized to avoid any fixa-
tion procedures. UDG treatment should be performed prior to 
sequencing of FFPE samples to minimize deamination artefacts in 
unmethylated CpG sites and non-CpG sites. MAF threshold adjust-
ment to 20% in analysis filter chain should be applied to remove 
maximum number of deamination artefacts, while retaining opti-
mal number of genuine mutations for TMB measurement as well as 
variant detection.
Overall, our pilot study has successfully optimized the 
Oncomine™ TML assay for measurement of TMB in HCC patients 
using FFPE and FF samples and highlights the challenges of recon-
structing TMB using untreated, archival material. In this context, we 
outline our suggested methodology to optimize TMB measurement, 
and recommend fresh tissue to provide the highest chance of reli-
able readings. Future research is needed to fully evaluate whether 
TMB is a suitable biomarker for immunotherapy response in HCC 
patients. However, our findings of low TMB in this cohort suggest 
that it might not be a suitable response biomarker for this emerging 
treatment modality.
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